Development and application of fully functional epitope-tagged forms of transforming growth factor-beta

Lawrence A Wolfraim¹, Gonnie M Alkemade, Biju Alex

¹Laboratory of Cell Regulation and Carcinogenesis, The National Cancer Institute, National Institutes of Health, Room C629, Building 41, 41 Library Drive, MSC 5055, Bethesda, MD 20892-5055, USA.

|July 23, 2002

Abstract:

Administration of transforming growth factor-beta (TGF-beta) has been found to be of therapeutic benefit in various mouse disease models and has potential clinical usefulness. However, the ability to track the distribution of exogenously administered, recombinant forms of these proteins has been restricted by cross-reactivity with endogenous TGF-beta and related TGF-beta isoforms. We describe novel FLAG- and hemagglutinin (HA)-tagged versions of mature TGF-beta1 that retain full biological activity as demonstrated by their ability to inhibit the growth of Mv1Lu epithelial cells, and to induce phosphorylation of the TGF-beta signaling intermediate, smad 2. Intracellular FLAG- and HA-TGF-beta1 can be detected in transfected cells by confocal immunofluorescence microscopy. We also describe sandwich ELISAs designed to specifically detect epitope-tagged TGF-beta and demonstrate the utility of these tagged ligands as probes for TGF-beta receptor expression by flow cytometry. The design of these fully functional epitope-tagged TGF-beta proteins should facilitate studies such as the evaluation of in vivo peptide pharmacodynamics and trafficking of TGF-beta ligand-receptor complexes.

Related Experiment Videos

Development and application of fully functional epitope-tagged forms of transforming growth factor-beta

Related Concept Videos

Ultrasound-guided selective occlusion of uteroplacental canal vessels in the mouse alters fetal growth and placental development.

Placental network differences among obstetric syndromes identified with an integrated multiomics approach.

Treatment of headache reduces blood pressure among most patients with migraine and elevated blood pressure.

Characterization of senescence-associated transcripts in the human placenta.

LOCC: a novel visualization and scoring of cutoffs for continuous variables with hepatocellular carcinoma prognosis as an example.

A Core NRF2 Gene Set Defined Through Comprehensive Transcriptomic Analysis Predicts Selective Drug Resistance and Poor Multicancer Prognosis.

Hybridoma-based generation of a functional IgM antibody targeting the 160-loop of influenza B virus haemagglutinin.

Dynamic effects of short-term storage temperature and duration on the transcriptome and functional pathways of umbilical cord blood-derived NK cells.

Instrument-specific reference intervals for coagulation factor XII and antithrombin III: A regional study in Jiangsu, China.

Antibody-pair based immunochromatographic sensor for analytical development and onsite monitoring of chromium contamination.

Influence of plate type on PBMC-based in vitro cytokine release assays for pre-clinical assessment of cytokine release syndrome.

EYRAplex platform for quantification of viral antigen-specific IgG responses.

[Innovative drug development: ethical and regulatory challenges].

Management of a Rare Digital Dermocutaneous Fibroma of the Flexor Tendon Sheath.

Development Timelines of Innovative Drugs in China: A 15-Year Cross-Sectional Analysis of Characteristics and Influencing Factors.

The emerging function of MYPT1 as a biomarker and therapeutic target.

Structure-uptake relationship study of trimeric cell-penetrating peptides with different arrangements.

Intraoperative transit-time flowmetry of the superficial temporal artery directly predicts and may mitigate risk of postoperative hyperperfusion syndrome in moyamoya bypass surgery.

Related Experiment Videos

Development and application of fully functional epitope-tagged forms of transforming growth factor-beta

Abstract:

Related Concept Videos

Related Articles